Tokyo Tape
Sign in
← Medipal Holdings

Quarterly report · Q1

7459.TEDINET S100RN8E
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥886.7bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥3.36T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥838.3bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥12.4bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥13.5bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥16.7bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥65.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥17.6bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥20.0bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥17.2bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥11.2bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥38.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥8.3bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥13.9bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥10.8bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥1.78Tat 2023-06-30Cons.Assets
Total assets¥1.71Tat 2023-03-31Cons.Assets
Total assets¥1.72Tat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥1.07Tat 2023-06-30Cons.Liabilities
Total liabilities¥1.02Tat 2023-03-31Cons.Liabilities
Net assets / equity¥710.1bnat 2023-06-30Cons.Net assets
Net assets / equity¥688.1bnat 2023-03-31Cons.Net assets
Net assets / equity¥659.0bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥200.2bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥195.0bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥52.322023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥184.822022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥39.392022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥179.122022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥36.942022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio32.7%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio32.8%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio31.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥903m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥903m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥49m
jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥28.9bn
jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥28.9bn
jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥0
jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥831m
jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥293.5bn
jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥293.4bn
jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥74m
jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥7.0bn
jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥565.2bn
jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥564.4bn
jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥828m
jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥4.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥887.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥886.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥903m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥12.4bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥913m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥913m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥98m
jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥18.5bn
jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥18.5bn
jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1m
jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥692m
jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥276.2bn
jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥276.2bn
jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥94m
jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥6.5bn
jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥544.4bn
jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥543.6bn
jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥817m
jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥6.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥839.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥838.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥913m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥13.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 380
ItemContextValueUnit
Compensation income eiCurrentYTDDuration1944000000JPY
Other eiPrior1YTDDuration8000000JPY
Other eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration3450000000JPY
Extraordinary incomeCurrentYTDDuration3338000000JPY
Loss on sales and retirement of noncurrent assets elPrior1YTDDuration2000000JPY
Loss on sales and retirement of noncurrent assets elCurrentYTDDuration5000000JPY
Impairment loss elPrior1YTDDuration0JPY
Impairment loss elCurrentYTDDuration21000000JPY
Loss on valuation of investment securities elPrior1YTDDuration3785000000JPY
Loss on valuation of investment securities elCurrentYTDDuration17000000JPY
Other elPrior1YTDDuration20000000JPY
Other elCurrentYTDDuration6000000JPY
Extraordinary lossPrior1YTDDuration3809000000JPY
Extraordinary lossCurrentYTDDuration51000000JPY
Income before income taxesPrior1YTDDuration17227000000JPY
Income before income taxesCurrentYTDDuration19963000000JPY
Income taxes currentPrior1YTDDuration11096000000JPY
Income taxes currentCurrentYTDDuration9654000000JPY
Income taxes deferredPrior1YTDDuration-4633000000JPY
Income taxes deferredCurrentYTDDuration-3638000000JPY
Income taxesPrior1YTDDuration6462000000JPY
Income taxesCurrentYTDDuration6016000000JPY
Profit lossPrior1YTDDuration10764000000JPY
Profit lossCurrentYTDDuration13946000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration2494000000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration2758000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration8270000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration11188000000JPY
Profit lossPrior1YTDDuration10764000000JPY
Profit lossCurrentYTDDuration13946000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration4661000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration7715000000JPY
Deferred gains or losses on hedges net of tax ociPrior1YTDDuration0JPY
Deferred gains or losses on hedges net of tax ociCurrentYTDDuration210000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-124000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration49000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration666000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration608000000JPY
Other comprehensive incomePrior1YTDDuration5203000000JPY
Other comprehensive incomeCurrentYTDDuration8584000000JPY
Comprehensive incomePrior1YTDDuration15968000000JPY
Comprehensive incomeCurrentYTDDuration22531000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration13440000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration19146000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration2528000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration3384000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember543628000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember276152000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember18547000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass